Goldman Sachs’s Phibro Animal Health PAHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.75M Buy
176,200
+15,301
+10% +$728K ﹤0.01% 3094
2025
Q4
$6.01M Buy
160,899
+32,072
+25% +$1.3M ﹤0.01% 3578
2025
Q3
$5.21M Sell
128,827
-62,513
-33% -$2.06M ﹤0.01% 3609
2025
Q2
$4.89M Sell
191,340
-5,490
-3% -$120K ﹤0.01% 3443
2025
Q1
$4.2M Sell
196,830
-47,412
-19% -$1.06M ﹤0.01% 3527
2024
Q4
$5.13M Sell
244,242
-99,027
-29% -$2.29M ﹤0.01% 3427
2024
Q3
$7.73M Buy
343,269
+116,334
+51% +$2.25M ﹤0.01% 2961
2024
Q2
$3.81M Buy
226,935
+4,517
+2% +$72.6K ﹤0.01% 3408
2024
Q1
$2.88M Buy
222,418
+27,129
+14% +$325K ﹤0.01% 3578
2023
Q4
$2.26M Buy
195,289
+42,626
+28% +$481K ﹤0.01% 3825
2023
Q3
$1.95M Sell
152,663
-2,400
-2% -$34K ﹤0.01% 3793
2023
Q2
$2.12M Sell
155,063
-217,982
-58% -$3.12M ﹤0.01% 3841
2023
Q1
$5.72M Sell
373,045
-5,913
-2% -$90.3K ﹤0.01% 2933
2022
Q4
$5.08M Buy
378,958
+23,802
+7% +$319K ﹤0.01% 3150
2022
Q3
$4.72M Sell
355,156
-271,081
-43% -$4.68M ﹤0.01% 3180
2022
Q2
$12M Sell
626,237
-59,233
-9% -$1.12M ﹤0.01% 2333
2022
Q1
$13.7M Buy
685,470
+10,065
+1% +$203K ﹤0.01% 2378
2021
Q4
$13.8M Buy
675,405
+35,466
+6% +$757K ﹤0.01% 2467
2021
Q3
$13.8M Sell
639,939
-8,758
-1% -$211K ﹤0.01% 2412
2021
Q2
$18.7M Buy
648,697
+35,112
+6% +$950K ﹤0.01% 2104
2021
Q1
$15M Buy
613,585
+242,906
+66% +$5.49M ﹤0.01% 2188
2020
Q4
$7.2M Sell
370,679
-6,671
-2% -$123K ﹤0.01% 2708
2020
Q3
$6.57M Buy
377,350
+84,390
+29% +$1.8M ﹤0.01% 2691
2020
Q2
$7.7M Sell
292,960
-66,422
-18% -$1.65M ﹤0.01% 2453
2020
Q1
$8.69M Sell
359,382
-13,901
-4% -$340K ﹤0.01% 2188
2019
Q4
$9.27M Sell
373,283
-18,200
-5% -$422K ﹤0.01% 2487
2019
Q3
$8.35M Buy
391,483
+52,581
+16% +$1.44M ﹤0.01% 2462
2019
Q2
$10.8M Sell
338,902
-161,999
-32% -$5.08M ﹤0.01% 2305
2019
Q1
$16.5M Buy
500,901
+45,881
+10% +$1.43M 0.01% 2034
2018
Q4
$14.6M Buy
455,020
+50,597
+13% +$1.91M ﹤0.01% 2052
2018
Q3
$17.4M Sell
404,423
-16,840
-4% -$796K ﹤0.01% 2024
2018
Q2
$19.4M Sell
421,263
-67,130
-14% -$2.97M 0.01% 1896
2018
Q1
$19.4M Buy
488,393
+12,002
+3% +$444K 0.01% 1884
2017
Q4
$16M Buy
476,391
+69,063
+17% +$2.45M ﹤0.01% 2119
2017
Q3
$15.1M Buy
407,328
+239,735
+143% +$9M ﹤0.01% 2224
2017
Q2
$6.21M Buy
167,593
+103,497
+161% +$3.38M ﹤0.01% 2883
2017
Q1
$1.8M Buy
64,096
+8,157
+15% +$230K ﹤0.01% 3853
2016
Q4
$1.64M Buy
55,939
+43,663
+356% +$1.19M ﹤0.01% 4037
2016
Q3
$334K Sell
12,276
-80,731
-87% -$1.83M ﹤0.01% 5395
2016
Q2
$1.74M Buy
93,007
+8,997
+11% +$188K ﹤0.01% 3743
2016
Q1
$2.27M Sell
84,010
-40,566
-33% -$1.16M ﹤0.01% 3356
2015
Q4
$3.75M Buy
124,576
+47,469
+62% +$1.52M ﹤0.01% 3101
2015
Q3
$2.44M Buy
77,107
+20,127
+35% +$735K ﹤0.01% 3600
2015
Q2
$2.22M Sell
56,980
-30,490
-35% -$1.05M ﹤0.01% 3734
2015
Q1
$3.1M Buy
+87,470
New +$2.82M ﹤0.01% 3360

Other funds holding PAHC

Goldman Sachs's PAHC Position: Q1 2026 in Review

Goldman Sachs increased its Phibro Animal Health (PAHC) stake by 9.5% in Q1 2026, buying an estimated $728K and bringing the position to 176,200 shares worth $9.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3094.

Goldman Sachs first reported a position in PAHC in Q1 2015 and has held it in 45 quarters since. The position peaked at $19.4M in Q2 2018. 257 funds tracked by Wall St. Rank hold PAHC as of Q1 2026.

  • Goldman Sachs held 176,200 shares of Phibro Animal Health worth $9.75M as of Q1 2026.
  • Goldman Sachs bought 15,301 Phibro Animal Health shares in Q1 2026, an estimated $728K.
  • Phibro Animal Health made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3094 holding.
  • Goldman Sachs first reported a position in Phibro Animal Health in Q1 2015 and has held it in 45 quarters since.
  • Goldman Sachs's Phibro Animal Health position peaked at $19.4M in Q2 2018.
  • 257 funds tracked by Wall St. Rank held Phibro Animal Health as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.